Charles Minn, MD
Nephrology · Tacoma, WANPI 1508119736
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,287 of the $67,165 with a category attached, or 74.9%. 23 manufacturers reported payments, led by BTG International Inc. at 58.3% of the total. Reporting peaked in 2022 at $25,565 and has fallen 95.9% since, to $1,047 in 2025. Among nephrology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $302.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$39K
- AstraZeneca$14K
- Bayer$9K
- Johnson & Johnson$1K
- Vifor Pharma, Inc.$750
- Novo Nordisk$629
- plus $2K from 17 others
What the payments were for
- Consulting fees$6041%
- Speaking & faculty fees$50,28775%
- Travel & lodging$10,56116%
- Food & beverage$5,5008%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 87 | $39,126 |
| AstraZeneca | 37 | $14,263 |
| Bayer | 22 | $9,299 |
| Johnson & Johnson | 4 | $1,442 |
| Vifor Pharma, Inc. | 23 | $750 |
| Novo Nordisk | 15 | $629 |
| Outset Medical Inc | 3 | $432 |
| GSK | 2 | $208 |
| Amgen(2 entities) | 7 | $188 |
| Otsuka America Pharmaceutical, Inc. | 2 | $122 |
| Aurinia Pharma U.S., Inc. | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| Medtronic | 1 | $98 |
| Boehringer Ingelheim | 1 | $75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $67 |
| Bard Peripheral Vascular, Inc. | 1 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Fresenius USA Marketing, Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $28 |
| Lilly USA, LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Akebia Therapeutics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,165 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $34,450 |
| EliquisApixaban | 71 | $22,360 |
| FarxigaDapagliflozin Propanediol | 23 | $22,196 |
| ZenpepLipase/Protease/Amylase | 18 | $11,498 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,373 |
| EntrestoSacubitril/Valsartan | 16 | $4,982 |
| XareltoRivaroxaban | 15 | $4,271 |
| MyrbetriqMirabegron | 14 | $3,222 |
| TradjentaLinagliptin | 13 | $3,193 |
| Potassium Chloride | 43 | $2,380 |
| Levetiracetam | 36 | $2,342 |
| Atorvastatin Calcium | 130 | $2,025 |
| Gabapentin | 61 | $1,883 |
| Amlodipine Besylate | 102 | $1,312 |
| Furosemide | 82 | $1,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $75 | $37,64360 claims |
| AstraZenecaFarxiga | $14,263 | $22,19623 claims |
| GSKTrelegy Ellipta | $208 | $8,37312 claims |
| Johnson & JohnsonXarelto | $1,442 | $4,27115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 nephrology providers in Washington.
Other nephrology in Tacoma
- Amandeep GillTacoma$2K
- Myra CarreonTacoma$1K
- Shanza MujeebTacoma$1K
- Maria Rojas EscandonTacoma$698
- Kathrine TuttleSpokane$421K
- Osama AmroSeattle$395K
- Dmitri VasinBremerton$215K
- Ian de BoerSeattle$117K
- Nicolae LecaSeattle$101K
- Syeda AhmadSeattle$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.